GeneReach Biotechnology (4171) — Free Cash Flow Generation Index
GeneReach Biotechnology (4171) has a Free Cash Flow Generation Index of 0.62x as of December 2025. Free cash flow of NT$7.47 Million represents 1% of operating cash flow (NT$12.05 Million). See GeneReach Biotechnology (4171) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
GeneReach Biotechnology Free Cash Flow Generation Index (2018–2022)
Historical FCF Generation Index trend for GeneReach Biotechnology across 4 annual periods. Explore 4171 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Free Cash Flow Generation for GeneReach Biotechnology (2018–2022)
Year-by-year Free Cash Flow Generation Index for GeneReach Biotechnology. For the full company profile including market capitalisation, see GeneReach Biotechnology (4171) market capitalisation.
| Year | FCG Index | Free Cash Flow (TWD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.87x | NT$312.73 Million | NT$357.63 Million | NT$44.90 Million | ▼ -8.4% |
| 2021 | 0.95x | NT$333.20 Million | NT$348.99 Million | NT$15.79 Million | ▲ +54.5% |
| 2020 | 0.62x | NT$104.95 Million | NT$169.82 Million | NT$64.87 Million | ▲ +3.3% |
| 2018 | 0.60x | NT$3.44 Million | NT$5.74 Million | NT$2.31 Million | — |